Nuclear factor-κB as a predictor of treatment response in breast cancer
- 1 November 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 15 (6) , 405-411
- https://doi.org/10.1097/00001622-200311000-00001
Abstract
To examine the links of nuclear factor-kappa B (NF-kappa B) to treatment-induced signaling in breast cancer and to propose further studies to elucidate the role of NF-kappa B in breast cancer response to chemotherapy and radiation. The authors' group and others have investigated the clinical relevance of ubiquitously expressed NF-kappa B in breast cancer. Possibly through its effects on apoptosis, NF-kappa B has been implicated in tumor resistance to chemotherapy and radiation in many types of tumors. Furthermore, both in vitro and in vivo studies have shown that targeted inhibition of NF-kappa B can sensitize tumor cells to chemotherapy and radiation. The molecular mechanisms involved in chemotherapy-induced and radiation-induced cell death in breast cancer are not fully known, nor are the mechanisms of treatment resistance. NF-kappa B is a transcription factor for a number of genes involved in tumor progression and resistance to systemic therapies and is a major regulator of the apoptotic pathway. Gaining further insights into molecular factors such as NF-kappa B as biomarkers for treatment response may help clinicians predict treatment outcome and lead to the development of targeted therapeutics.Keywords
This publication has 91 references indexed in Scilit:
- Quality of Breast Cancer Care: What Do We Know?Journal of Clinical Oncology, 2002
- Nuclear transcription factor-κB as a target for cancer drug developmentLeukemia, 2002
- Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer*Journal of Surgical Oncology, 2002
- Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor‐negative breast cancer patientsInternational Journal of Cancer, 2002
- Specific protection against breast cancers by cyclin D1 ablationNature, 2001
- Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cellsCarcinogenesis: Integrative Cancer Research, 2000
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Effects of chemotherapy on breast cancer tissueHistopathology, 1997
- The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissueHuman Pathology, 1990